IO Biotech (IOBT) Stock Price, News & Analysis

Company Overview

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key Stats

• Today's Range: $1.18 to $1.23
• 50-Day Range: $0.75 to $1.64
• 52-Week Range: $0.73 to $2.10
• Volume: 111,002 shs
• Average Volume: 223,662 shs
• Market Capitalization: $79.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.33
• Consensus Rating: Buy

IO Biotech Stock Analysis - MarketRank™

IO Biotech scored higher than 55% of companies evaluated by MarketBeat, and ranked 517th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IO Biotech has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for IO Biotech are expected to remain at ($1.18) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of IO Biotech is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IO Biotech is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IO Biotech has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.71% of the float of IO Biotech has been sold short.

Short Interest Ratio / Days to Cover

IO Biotech has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IO Biotech has recently increased by 160.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IO Biotech does not currently pay a dividend.

Dividend Growth

IO Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.71% of the float of IO Biotech has been sold short.

Short Interest Ratio / Days to Cover

IO Biotech has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IO Biotech has recently increased by 160.03%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

IO Biotech has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for IO Biotech this week, compared to 1 article on an average week.

MarketBeat Follows

Only 3 people have added IO Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IO Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $68,524.00 in company stock.

Percentage Held by Insiders

Only 2.30% of the stock of IO Biotech is held by insiders.

Percentage Held by Institutions

54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IOBT Stock Analysis - Frequently Asked Questions

How have IOBT shares performed this year?

IO Biotech's stock was trading at $1.88 at the beginning of 2024. Since then, IOBT shares have decreased by 35.6% and is now trading at $1.21.
View the best growth stocks for 2024 here.

How were IO Biotech's earnings last quarter?

IO Biotech, Inc. (NASDAQ:IOBT) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.31) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.04.

When did IO Biotech IPO?

IO Biotech (IOBT) raised $111 million in an initial public offering (IPO) on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share.

How do I buy shares of IO Biotech?

Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of IO Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IO Biotech investors own include COMPASS Pathways (CMPS), Nkarta (NKTX), PayPal (PYPL), AbCellera Biologics (ABCL), Atai Life Sciences (ATAI), Meta Platforms (META) and Palantir Technologies (PLTR).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 10/17/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IOBT
• CUSIP: N/A
• CIK: 1865494
• Web: www.iobiotech.com
• Phone: 45-7070-2980
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.33
• High Stock Price Target: $12.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +671.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-86,080,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.05%
• Return on Assets: -62.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.84
• Quick Ratio: 7.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.02 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 65,881,000
• Free Float: 64,366,000
• Market Cap: $79.72 million
• Optionable: Not Optionable
• Beta: 0.46